Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gilbert

Showing results (131-140 of 157) with videos related to

Pageof 16
Sort By:
Journal for Immunotherapy of Cancer|January 22, 2022
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm studyAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Journal for Immunotherapy of Cancer|November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancerIgnace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2026
Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological featuresKattreen Hanna, Gabriel Levin, Miryam Al Nasir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
JAMA Network Open|November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled TrialThierry André, Dominique Berton, Giuseppe Curigliano, et al.
JAMA|January 6, 2011
DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumorsThomas Rio Frio, Amin Bahubeshi, Chryssa Kanellopoulou, et al.
Therapeutic Advances in Medical Oncology|September 30, 2024
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Annika Auranen, Matthew A Powell, Vladyslav Sukhin, et al.
Pageof 16

Showing results (131-140 of 157) with videos related to

Sort By:
Pageof 16
Journal for Immunotherapy of Cancer|January 22, 2022
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm studyAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Journal for Immunotherapy of Cancer|November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
British Journal of Cancer|April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerYvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancerIgnace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA TrialJosep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 6, 2026
Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological featuresKattreen Hanna, Gabriel Levin, Miryam Al Nasir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancerR Wendel Naumann, Robert L Coleman, Robert A Burger, et al.
JAMA Network Open|November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled TrialThierry André, Dominique Berton, Giuseppe Curigliano, et al.
JAMA|January 6, 2011
DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumorsThomas Rio Frio, Amin Bahubeshi, Chryssa Kanellopoulou, et al.
Therapeutic Advances in Medical Oncology|September 30, 2024
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Annika Auranen, Matthew A Powell, Vladyslav Sukhin, et al.
Pageof 16